Decitabin / Cedazuridin (2) – Inaqovi®
Acute myeloid leukaemia, first-line treatment, combination with venetoclax
Characteristics
| Start date | 15.07.2026 |
|---|---|
| Resolution | 07.01.2027 – active procedure |
| INN | Decitabin/Cedazuridin |
| Brand name | Inaqovi® |
| Pharm. company | Otsuka Pharma GmbH |
| G-BA Procedure ID | D-1342 |
| Therapeutic area | Oncological diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Decitabin / Cedazuridin (2) | Inaqovi® | Otsuka Pharma GmbH | Acute myeloid leukaemia, first-line treatment, combination with venetoclax | n.d. | active procedure | |
| Decitabin / Cedazuridin (1) | Inaqovi® | Otsuka Pharma GmbH | Acute myeloid leukaemia, first line | 560–840 | 100% additional benefit not proven |
<< List of all resolutions